EU ASMF registration gives an active-substance manufacturer a way to back a marketing-authorization applicant without handing that applicant its trade secrets. The work goes through CESP as a decentralized or mutual-recognition procedure, and the file comes in two halves: an Applicant's Part and a Restricted Part. Most teams move from CESP setup through number request, eCTD build and submission in a few months.

What the EU ASMF procedure is and why it matters

An Active Substance Master File, or ASMF, is how an active-substance maker puts its chemistry data in front of a regulator while keeping it away from the finished-product applicant. The legal hook is Directive 2001/83/EC, Annex I, Part I, point 3.2, paragraph (8). The current procedural guideline is the EMA Guideline on Active Substance Master File Procedure (CHMP/QWP/227/02 Rev4/Corr, effective 17 June 2019).

The design does one job well. The applicant and the marketing-authorization holder take full responsibility for the medicine and for the active substance's quality. The ASMF lets the regulator see what it needs about the substance while the applicant sees only what it must. That split is why the file is built in two independent parts. Anyone planning EU ASMF registration should internalize this two-part split first.

Aspect	Applicant's Part (AP)	Restricted Part (RP)
What it holds	The part shared with the formulation applicant, forming Module 3 of its MAA	Process details such as reaction conditions, temperatures and key-step validation data, kept confidential
Who receives it	The formulation applicant and the authorities	Only the ASMF holder submits it direct to the authorities
Confidentiality	Still confidential; do not share with third parties without the holder's written consent	Confidential; not shared with the applicant

ASMF is one of two main routes for bringing an active substance into the EU. The other is the Certificate of Suitability, or CEP, which EDQM issues. The two routes are fully independent.

Aspect	ASMF	CEP
Full name	Active Substance Master File, also called EDMF	Certificate of Suitability to the European Pharmacopoeia
Issued by	No central number for the route itself; the EU/ASMF number comes from the RMS	EDQM
Best for	Substances not covered by a pharmacopoeia monograph	Substances with a European Pharmacopoeia monograph
Key rule	One MAA should reference ASMF or CEP for a given substance, not both	Supplementary information may be supplied as an ASMF only when the CEP lacks data, for example stability

One MAA should reference ASMF or CEP for a given substance, not both. The only exception is when the CEP lacks some data, such as stability, and the authority accepts the gap filled as an ASMF. The ASMF procedure must not be used for biological active substances, including immunological, blood or plasma derived, biotech and homeopathic products (see Annex 5 of the procedure guideline). A holder may own both an ASMF and a CEP for one substance across different projects, but the route for this filing is fixed at project start.

The EU ASMF registration pathway at a glance

EU ASMF registration is a staged job, and the sequence is not flexible. Get the account and the number in place before the dossier is final, because both depend on details from the formulation applicant's procedure.

1. Open a CESP account, ideally at least a month before any submission.

1. Ask the reference member state for an EU/ASMF number once you have the MAA procedure details.

1. Build the eCTD dossier: Module 1, the quality overview (M2.3) and the substance detail (M3.2.S), in both AP and RP versions.

1. Submit through CESP and line up the ASMF date with the applicant's MAA date.

Each step has its own traps, and the sections below follow the order a project actually hits them.

Step 1: Open a CESP account early

For human medicines, eCTD is mandatory. The centralized procedure required it from 1 July 2016, DCP and MRP from 1 January 2018, national-procedure new marketing authorizations from 1 July 2018, and the remaining submission types from 1 January 2019. Under DCP, MRP or the national procedure, the ASMF goes in through CESP, the Common European Submission Platform, so the account is the real starting gate. EU ASMF registration cannot proceed on CESP without it.

The registration itself is simple but slow if left late. Go to the CESP portal and register a new organization. Enter the company and contact details, then submit. The CESP team sends a confirmation email; check the spam folder, because mail rules often file it as junk. That email carries a registration ID and asks for a power of attorney from the legal representative, on company letterhead with a handwritten signature, uploaded through the link it contains. After the power of attorney is uploaded, the success notice normally arrives within about three working days.

Three points save grief later. The account is a prerequisite for submission, so open it at least a month ahead. After login, switch on every notification under Subscriptions so each status change reaches you. The member-state contact mailboxes also sit under Latest Updates on CESP, which cross-checks against the CMDh Contact Points file on the HMA site.

Step 2: Request an EU/ASMF number

The DCP route does not force you to hold an ASMF number before filing, but doing so is strongly advised. EU ASMF registration that skips this step forfeits the reuse benefit. The EU/ASMF number is synced to the EU CTS ASMF assessment repository, so prior assessment records for the same substance can be found and reused, which shortens later reviews. You must apply to the reference member state before the formal filing, and you cannot apply without the future MAA's procedure number. Pull the procedure number, member-state composition and expected submission date from the formulation applicant first.

Do not mix the two number families. They are independent and cannot be swapped.

Item	EMEA/ASMF/1xxxxx	EU/ASMF/xxxxx
Procedure type	Centralized procedure (CP)	Worksharing procedure (DCP, MRP or NP; the RMS writes the full assessment report)
Issued by	EMA	The RMS competent authority (coordinated by CMDh), or EMA
Application form	EMA PAM submission form (EMA website)	EU ASMF number request form (HMA website, CMDh/307/2013 Rev.4, July 2024 edition)
How to submit	Through the EMA eSubmission system	Email the completed form to the RMS designated mailbox
Turnaround	Processed after EMA receives it	About 10 days officially; usually 3 to 4 working days in practice

The two systems are independent and non-interchangeable. One ASMF must not carry both an EMEA/ASMF and an EU/ASMF number, or validation fails. A substance that already holds an EMEA/ASMF number for the centralized procedure still needs a separate EU/ASMF number for a DCP filing. The number stays fixed for the ASMF's whole life; later updates never need a new one.

The application runs like this. Download the EU ASMF number request form from the HMA CMDh Working Group on Active Substance Master File Procedures page (current CMDh/307/2013 Rev.4, July 2024). Fill in the holder name and address, the substance name (INN, including salt or hydrate form), the internal API code, the AP and RP version numbers for this submission, any prior assessment history, and the linked DCP information with its expected submission date. Write in English and have the holder's authorized signatory sign. Get the RMS request mailbox from the latest CMDh Contact Points table (it changes, so use the newest), on the row Request for EU ASMF number. Send the email with a clear subject and the completed form attached. If the RMS wants more, reply within 24 to 48 hours. The number normally arrives within about 10 days; in practice 3 to 4 working days is common, and one holder received it in 2 working days. Past 10 days with nothing, a polite follow-up and a check of the mailbox address are warranted.

Timing is tight by design. The number must not be requested earlier than two weeks before the MAA's planned submission date; send it one to two weeks before. Too early and it can be rejected or pushed back to re-apply. One EU/ASMF number maps to one worksharing event and is bound to the DCP flow.

Worksharing is worth adopting even though it is not mandatory. Under EMA/CMDh/CMDv/308/2013 (current 2025-12 edition), the first DCP to use the ASMF becomes the parent procedure, and the RMS-drafted assessment report is filed to the EU ASMF database. Later procedures that cite the same ASMF become daughter procedures and reuse that report, avoiding duplicate review and conflicting conclusions. Worksharing does not change the MAA's statutory timeline. The moment you receive the number, tell the formulation applicant so it lands correctly in the MAA, and add it to the ASMF Cover Letter, Letter of Access and Submission Details Form.

Step 3: Compile the eCTD dossier

EU ASMF registration dossiers follow the CTD format. For a first submission the relevant modules are M1 (administrative), M2.3 (the quality overall summary, or QOS) and M3.2.S (substance detail), and you prepare both an AP and an RP version of M2 and M3. The substance chemistry is written against the EMA Active Substance Chemical Guideline. The current version is EMA/CHMP/QWP/49484/2026, adopted by CHMP on 16 February 2026 and effective 1 September 2026, replacing the 2016 version (EMA/454576/2016). This revision tightens three areas that in-progress projects should self-check:

• Nitrosamine risk: the scope now reaches nitrosamine precursors, and the starting-material risk assessment must cross-reference the discussion in section 3.2.S.3.2.

• Starting-material selection: ICH Q11 principles are enforced, and commercially available is no longer a sufficient justification. The process flow diagram must include processing aids, and the block flow diagram moves from recommended to default.

• Recovery and reprocessing: separate routine from occasional reprocessing. Routine reprocessing must sit inside the registered process and align with EU GMP Part II.

The M1 templates come from the EMA eASMF eSubmission site, which also ships a full eCTD example (asmf-eurotriptan-maleate) worth using as a folder skeleton. The M1 practical points that trip teams up are:

1. Draft a Letter of Access and a Submission Letter for each RMS and CMS. The Letter of Access follows the procedure guideline Annex 2 template on company letterhead. It is submitted once per MAA applicant; later new access letters use the next eCTD sequence. Add the EU/ASMF number to the Letter of Access once received; some agencies ask for a revision. Poland requires the paper originals of the Letter of Access and Submission Letter by post, so build in mailing time.

1. Tracking Table: the official template does not require it, but some agencies do, and missing it fails eCTD validation. The ASMF Tracking Table need not match the MAA's complexity; first submission just states that it is a first filing with the date, and later sequences state which countries and dates each sequence went to. Place it in M1.0 as a common national document.

1. German authority heading: the Letter of Access to Germany must name the authority exactly as Federal Institute for Drugs and Medical Devices (BfArM). On CESP, Germany has two entries, DE(BfArM) for medicinal products and DE(PEI) for combination products, so pick the right one.

1. Submission Details Form (M1.8): collect the ASMF number, procedure number, version numbers and any prior ASMF filing history across EU member states. Under DCP, disclose prior submissions honestly so conclusions can be reused.

1. Other M1 points: M1.0 cover letter per the guideline Annex template, listing every member state; M1.4.1 quality expert statement (quality expert only); M1.5 GMP certificates for all sites plus a EU GMP Part II statement; M1.3, M1.6 and environmental risk assessment normally marked not applicable because the MAA covers them.

Version control and the eCTD lifecycle deserve real care. AP and RP each hold their own continuous version numbering, recommended as API code/AP/version x/date and API code/RP/version x/date. Every update, major or minor, gets a new version number with a date, and the sequence stays continuous. The QOS front page shows the current version and date; the AP front page travels with the AP copy to the applicant so the authority can confirm alignment. For an update, submit only the changed CTD sections with their eCTD attributes, plus a change comparison table in Module 1 that spells out each change as current wording to proposed wording.

One ASMF keeps a single eCTD lifecycle. All its sequences share one UUID, related-sequence stays 0000, the envelope submission type is asmf, the first submission unit is initial and every later one is response. When the ASMF serves several procedures, submit all prior sequences plus one new sequence that holds only Module 1. Do not rebuild the 0000 sequence for each new procedure, or you create parallel lifecycles and miss updates. When sending to multiple authorities, the envelope procedure type is mutual-recognition regardless of the medicine's actual procedure type. The AP you give the applicant must match the AP you give the authority exactly, and the MAA normally expects the latest ASMF version; any difference in the API specification needs a reasoned explanation.

Step 4: Submit through CESP

With the dossier ready, log in to CESP and create a New Delivery File. The final act of EU ASMF registration is this CESP submission. Fill in the submission information for the formulation DCP, then tick the RMS and every CMS country one by one. Missing a member state blocks that state's review, and Germany must be split into DE(BfArM) and DE(PEI). If a CMS does not appear in the dropdown, use the zz placeholder.

After submitting the form, the system generates an XML Delivery File for download. It cannot be edited: if anything is wrong you create a new one. The compression format you declare must match the one you built, and the file name must not change. The Delivery File is single use. In Web Upload (Integrated Upload), upload the eCTD package first and the Delivery File XML second. The order is mandatory; reversing it invalidates the submission. You can then watch delivery and per-country receipt status under Delivery.

Timing rules bind the ASMF to the MAA. The ASMF must not be submitted earlier than one month before the MAA's planned submission date, and not later than the MAA submission day. The holder should align dates with the applicant and keep at least two weeks of buffer for CESP technical issues and validation failure.

Version consistency at first DCP submission is strict. The ASMF version and content sent to the RMS and to every CMS must be identical. Individual countries may ask for extra M1 items such as translations, which go into that country's M1.

The DCP review timeline and who answers what

Milestone day	Milestone	ASMF holder responsibility
Day 0	The formulation applicant submits the MAA; the ASMF holder submits the full ASMF (AP plus RP) via CESP	Confirm the ASMF is correctly linked and passes validation
Day 0 to 14	The RMS and each CMS run technical validation	Watch CESP and official notices; fix validation defects promptly; agencies then raise M1 administrative queries
Day 70	The RMS issues the preliminary assessment report (PrAR)	Receive ASMF questions relayed through the applicant
Day 100	Each CMS submits comments on the PrAR	Watch whether any CMS raises extra questions
Day 105 to 120	Deficiency responses (DCP response due Day 105)	Answer after the final question list is set; copy AP answers to the applicant and fold them into its response; if the ASMF itself changes, update the version and send to all member states
Day 150 to 210	The RMS issues the final AR; each CMS decides	Prepare an updated ASMF if a revision is needed
Day 210 plus	Each member state enters the national phase	Supply extra documents per country (translations); build a post-approval change system

Questions route by part. Questions on the AP go to both the applicant and the ASMF holder; questions on the RP go only to the holder. The holder sends AP and RP answers direct to the authority, copying the applicant on AP answers, and the applicant folds the AP answers into its own response. The full assessment report (AP plus RP) goes to the holder; only the AP part goes to the applicant. The ASMF assessment report is not public; only the AP part appears as an active-substance summary in the medicine's EPAR or PAR.

On GMP, the substance manufacturing sites should already hold a valid EU GMP certificate or be in the inspection plan before the procedure starts. Authorities check site GMP status during ASMF review and may trigger an inspection. One holder's experience is that once the MAA qualified person issues the QP declaration for the active-substance site, the chance of a triggered inspection drops to very low.

Lifecycle and variation management

Sound EU ASMF registration practice means the holder keeps the file consistent with the real manufacturing process and with current registered and scientific requirements. No change to ASMF content, such as process or specification, may be made without notifying every applicant, every marketing-authorization holder, and every authority or EMA. That duty lasts until the Letter of Access is withdrawn.

Any ASMF change is reported by each marketing-authorization holder through the appropriate variation procedure, using the EU variation Type IA, IB or II grading. The ASMF holder submits the updated sections, an updated QOS and a change comparison table. Module-1-only updates, such as adding a new Letter of Access, do not change the ASMF version number. At the five-year renewal, the marketing-authorization holder must declare that product quality has been kept current through variation procedures; it confirms this with the ASMF holder, and any unreported change starts a variation at once. Where one substance has substantially different synthetic routes or different specifications, separate ASMFs each get their own number; minor route differences stay in a single ASMF.

Common pitfalls and how to avoid them

Risk	Consequence	How to avoid
Mixing EMEA/ASMF with EU/ASMF numbers	The ASMF cannot be correctly referenced by the MAA; validation fails	Confirm procedure type at project start; use EU/ASMF for DCP, MRP or NP and EMEA/ASMF for CP; reference only one
Applying for the number too early (before T-2 weeks)	Rejected or asked to re-apply	Plan backwards from the T-2 week window; send the request at T-10 to T-7 days
Missing a member state when ticking the Delivery File	That state never receives the ASMF; its review cannot start	Tick RMS plus every CMS one by one; split BfArM and PEI for Germany
Wrong upload order (XML before the package)	Submission invalid	Always upload the eCTD package first, then the Delivery File
AP version mismatch between customer and authority	Confused or rejected review	Run a version-management process; show version and date on the AP front page; reconcile before submission
Non-sequential version numbers or date-only changes	Authority cannot confirm it has every version	Assign a new version number with a new date on every update; keep the sequence continuous
Rebuilding the 0000 sequence for each new procedure	Multiple parallel lifecycles for one ASMF; missed updates	Maintain one eCTD lifecycle for the ASMF's life (one UUID); for a new procedure submit all prior sequences plus one new M1-only sequence
Missing the Tracking Table	Some agencies fail eCTD validation	Attach a short Tracking Table at first submission; later sequences keep a sequence-country-date map
Poland LOA and Submission Letter originals	Formal review blocked	Arrange paper originals by post early; build in lead time
Incomplete German authority heading	Asked to revise, delaying validation	Write the exact full name "Federal Institute for Drugs and Medical Devices"
Status emails landing in spam	Missed validation or review deadlines	Subscribe to all CESP notices and check spam regularly
Weak starting-material justification or incomplete nitrosamine assessment	Easy to trigger a deficiency or even a major objection under the 2026 chemical guideline	Self-check against EMA/CHMP/QWP/49484/2026 before submission; carry the risk assessment and control strategy through

Key guidelines and forms you will need

Document	Number or version	Source
Active Substance Master File procedure guideline	CHMP/QWP/227/02 Rev4/Corr (effective 2019-06-17)	EMA
ASMF questions and answers	CMDh/CMDv/280/2012 Rev.12 (2022-11)	HMA/CMDh
ASMF eCTD submission harmonized technical guideline	EMA/725135/2017 v2.3 (2020-07-01)	EMA eSubmission
EU M1 eCTD specification	v3.1 (2023-11, with v3.1.1 implementation guide and validation criteria update)	EMA eSubmission
ASMF assessment worksharing procedure	EMA/CMDh/CMDv/308/2013 (2025-12 edition)	HMA
EU ASMF number request form	CMDh/307/2013 Rev.4 (2024-07)	HMA
CMDh contact points list	Continuously updated (use the latest)	HMA
Active substance chemical guideline	EMA/CHMP/QWP/49484/2026 (effective 2026-09-01)	EMA
MRP/DCP eCTD use best practice guideline	CMDh/084/2008 (use the latest HMA edition)	HMA

Bottom line

EU ASMF registration succeeds on preparation first and detail second. Passing validation is only the start; the deficiency responses during the long technical review need tight coordination between the ASMF holder and the formulation applicant. Lock the CESP account and the EU/ASMF number early, keep one eCTD lifecycle and one continuous version sequence, and self-check the dossier against the 2026 chemical guideline before you submit. Treat the number, the timelines and the worksharing link as fixed commitments, and the procedure becomes a manageable project rather than a moving target.

FAQ

What is an ASMF in EU regulatory terms

An ASMF, or Active Substance Master File, is a confidential submission that lets an active-substance manufacturer place its chemistry data before a medicines regulator while withholding it from the finished-product applicant. It supports a marketing authorization application without the applicant seeing the holder's process secrets. The legal basis is Directive 2001/83/EC Annex I Part I point 3.2 paragraph 8, and the live guideline is EMA CHMP/QWP/227/02 Rev4/Corr. The file splits into an Applicant's Part shared with the applicant and a Restricted Part seen only by the authority.

How does ASMF differ from a CEP

ASMF and CEP are the two main routes for an active substance to enter the EU, and they are independent. A CEP is issued by EDQM for substances that have a European Pharmacopoeia monograph, while an ASMF is built by the holder for substances not covered by a monograph. One marketing authorization should reference ASMF or CEP for a given substance, not both. The only overlap is when a CEP lacks data such as stability and the authority accepts that gap filled as an ASMF. The ASMF procedure cannot be used for biological active substances.

Can I use both ASMF and CEP in one MAA

No. For a given active substance in one MAA you should reference either ASMF or CEP, not both. The two are fully independent routes and mixing them causes validation failure. The single exception is when the CEP does not contain enough information, for example stability data, and the authority accepts the missing part supplied as an ASMF. Even then the primary route stays one of the two. A holder may own both an ASMF and a CEP for the same substance across different projects, but must choose the route at project start.

Why request an EU/ASMF number before filing

The EU/ASMF number is synced to the EU CTS ASMF assessment repository, so prior assessment records for the same substance can be found and reused, which shortens later reviews. Although the DCP route does not mandate a number before filing, requesting it early is strongly advised. EU ASMF registration that skips this step forfeits the reuse benefit. You cannot apply without the future MAA's procedure number, so the formulation applicant must first share its DCP details. The number then stays fixed for the ASMF's whole life and is written into the MAA, the Cover Letter, the Letter of Access and the Submission Details Form.

When should I apply for the EU/ASMF number

Apply no earlier than two weeks before the MAA's planned submission date, and ideally one to two weeks before. Applying too early can be rejected or pushed back to re-apply, because one number maps to one worksharing event bound to the DCP flow. A practical send window is T-10 to T-7 days before the MAA submission. You must already know the procedure number, member-state composition and expected submission date from the formulation applicant before you send the request form to the RMS mailbox.

How long does it take to get an EU/ASMF number

Officially the RMS aims to issue the number within about 10 days of receiving the request. In practice most holders receive it in 3 to 4 working days, and fast cases of 2 working days are reported. If 10 days pass with no number, send a polite follow-up and verify that you used the current CMDh Contact Points mailbox address. The request form is CMDh/307/2013 Rev.4 from July 2024, emailed to the RMS designated mailbox rather than submitted through a portal.

What is ASMF worksharing and is it mandatory

Worksharing lets several procedures reuse one assessment report for the same ASMF. Under EMA/CMDh/CMDv/308/2013, the first DCP to use the ASMF is the parent procedure and its RMS-drafted assessment report is filed to the EU ASMF database. Later procedures citing the same ASMF are daughter procedures that reuse that report, avoiding duplicate review and conflicting conclusions. It is recommended but not mandatory, and it does not change the MAA's statutory timeline. You should still tell the applicant the number as soon as you receive it.

Which eCTD modules does an ASMF submission include

A first ASMF submission covers Module 1 (administrative), M2.3 (the quality overall summary or QOS) and M3.2.S (substance chemistry detail). You prepare both an Applicant's Part and a Restricted Part for M2 and M3. The substance chemistry is written against the EMA Active Substance Chemical Guideline, currently EMA/CHMP/QWP/49484/2026 effective 1 September 2026. M1 specifics include the Letter of Access, a Tracking Table, the Submission Details Form and country-specific items such as the exact German authority name.

What is the Letter of Access in an ASMF

The Letter of Access is the document by which the ASMF holder grants the applicant the right to refer to the ASMF in its MAA. It follows the procedure guideline Annex 2 template on company letterhead and is submitted once per MAA applicant, with later new access letters using the next eCTD sequence. The EU/ASMF number is added once received, and some agencies ask for a revision. Poland requires the paper originals of the Letter of Access and Submission Letter by post, so mailing lead time must be built in before submission.

How are ASMF questions and answers routed during review

Questions on the Applicant's Part go to both the applicant and the ASMF holder, while questions on the Restricted Part go only to the holder. The holder answers direct to the authority and copies the applicant on AP answers, and the applicant folds those answers into its own response. The full assessment report covering AP and RP goes to the holder, but only the AP part goes to the applicant. The ASMF assessment report stays non-public, and only the AP portion appears as an active-substance summary in the medicine's EPAR or PAR.

What are the most common ASMF submission errors

The repeated errors are mixing EMEA/ASMF with EU/ASMF numbers, requesting the number too early, missing a member state on the Delivery File, uploading the XML before the package, AP version mismatch, and non-sequential version numbers. Others are rebuilding the 0000 sequence per procedure, omitting the Tracking Table, and forgetting Poland's paper originals. Weak starting-material justification or an incomplete nitrosamine assessment is a frequent trigger for deficiencies under the 2026 chemical guideline. Each of these is avoidable with a pre-submission checklist.

How do I manage ASMF variations after approval

Any change is reported by each marketing authorization holder through the EU variation procedure using Type IA, IB or II grading, and the ASMF holder submits updated sections, an updated QOS and a change comparison table. Module-1-only updates such as a new Letter of Access do not change the version number. At five-year renewal the holder confirms product quality has been kept current, and any unreported change starts a variation immediately. Substantially different synthetic routes or specifications get separate ASMFs with their own numbers, while minor differences stay in one file.